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ABSTRACT 
Aim: To report a series of thirty cases of bisphosph- 
onate-related osteonecrosis of the jaw (BRONJ). Ma- 
terial and Methods: For 30 patients with BRONJ, 
gender, age, underlying diagnosis, type of bisphos- 
phonate (BP), administration route and duration, 
location and stage of osteonecrosis, symptoms and 
oral health status, radiological findings of the jaws, 
treatment and outcome, were recorded. Results: Un- 
derlying diagnoses in the series (12 male; 18 female; 
mean age 70.50 ± 9.62) were: 12 multiple myeloma, 7 
breast cancer, 3 prostate carcinoma, 1 kidney/lung/ 
bladder/mediastinal cancer, 1 chronic lymphocytic 
leukemia, 1 osteoporosis, 1 palatal osteosarcoma + 
osteoporosis, 1 non-Hodgkin’s lymphoma. Forty-se- 
ven osteonecrotic lesions were detected; 30 localized 
in the mandible, 17 in the maxilla; trigger events were 
tooth extraction in 31 cases (66%), periodontal dis- 
ease in 4 (8.50%), incongruous dentures in 3 (6.40%), 
perimplantitis in 1 (2.10%), unknown in 8 (17%). 
Twenty-nine patients had received treatment using 
amino bisphosphonates (25 zoledronate, 2 pamidro- 
nate, 2 alendronate) and 1 clodronate; the admini- 
stration route was intravenous in 27 patients, oral in 
2 and intramuscular in 1. Mean number of doses to 
bone exposure for patients was 34.11 for zoledronate, 
50.50 for pamidronate, 146 for alendronate, and 500 
for clodronate. Among statistical data the only sig- 
nificant finding was that panoramic dental radiogra- 
phy gave no concrete support for diagnosis of ONJ 
lesions (p ≤ 0.04). Conclusions: Our case series re- 
flects literature data. We emphasize the insufficient 
role of panoramic radiography to study osteonecrotic 
lesions and the role of poor oral hygiene. 
 
Keywords: Bisphosphonates; Jaws; Osteonecrosis;  
Panoramic Radiograph; Dental Hygiene 
1. INTRODUCTION 
Bisphosphonates (BPs) are a class of drugs derived from 
pyrophosphates, endogenous inorganic regulators of 
mineralization, by substituting the oxygen atom in the 
basic pyrophosphate chain with a carbon; this leads to 
osteoclast inhibition, decreasing bone resorption [1-3]. 
Different generations of BPs have been created, with 
distinct pharmacological potency [1-3]. The first genera- 
tion of BPs comprises etidronate and clodronate, charac- 
terized by a chlorine atom. The second generation of BPs 
comprises alendronate and pamidronate, in which an 
amino-terminal group has been introduced; these drugs 
have antiresorptive potency that is 10 - 100 times higher 
than that of etidronate and clodronate. Zoledronate is a 
BP of the third generation, and has an imidazole ring 
group in the side chain with the potency about 100 times 
higher than pamidronate. The administration route for 
clodronate is intramuscular or oral or intravenous, for 
alendronate it is oral, and for pamidronate and zoledro- 
nate it is only intravenous [1-3]. The effects of BPs in- 
clude the reduction of bone loss and of the risk of patho- 
logical fractures; these drugs are thus administered to 
patients suffering from destructive bone lesions resulting 
from osteoclast-induced resorption [3-5]; they are mainly 
used to treat and prevent malignant hypercalcemia, 
skeletal-related events associated with bone metastases 
secondary to solid cancer, and in the management of the 
lesions of multiple myeloma, Paget’s disease, primary 
and secondary hyperparathyroidism and osteoporosis 
[2-11]. Starting from 2003, reports began to appear of 
necrotic bone exposure of the jaw [12,13] in patients 
receiving BPs for multiple myeloma and bone cancer 
metastases: the osteonecrotic lesions are now known as 
bisphosphonate-related osteonecrosis of the jaw (BRONJ) 
[14,15]. This phenomenon has mainly been observed 
after intravenous administration of BPs containing ni- 
trogen [9,12,14-26]. Following the early reports, several  
Published Online July 2013 in SciRes. http://www.scirp.org/journal/ojst 
M. Migliario et al. / Open Journal of Stomatology 3 (2013) 247-254 248 
other cases of BRONJ have also been reported in osteop- 
orosis patients treated with BPs [27-32]. This study re- 
ports on 30 patients with jaw exposure who had under-
gone treatment with BPs.  
2. MATERIAL AND METHODS 
2.1. Sample 
The study received permission from the local ethics 
committee (EC study protocol 61/10) and was carried out 
in accordance with the ethical standards of the Helsinki 
Declaration of 1964. Thirty patients with jaw bone ex- 
posure of at least 8 weeks duration, with no history of 
head and neck radiation therapy, history positive for BPs 
therapy and negative for local radiation therapy, who had 
been referred to our Department between May 2005 and 
December 2011 were enrolled. After being informed of 
the aims and methods of the study, patients gave their 
written consent to participation. Sex, age, underlying 
diagnosis, type, duration, and administration route of BP 
treatment, time of onset of ONJ, treatment and outcome 
were recorded for all patients. The disease stage was 
registered according to AAOMS staging system [14,15]. 
Oral examination determined oral health status, indexes 
of oral hygiene (GI, gingival index as per Löe and Sil- 
ness; PI, plaque index, as per Silness and Löe) [33,34], 
location, size, and clinical symptoms of osteonecrosis. 
Data from instrumental analysis was also recorded. 
2.2. Statistical Analysis 
Statistical analysis was performed using SPSS (SPSS Inc. 
Chicago, US) for Windows, version 12, with p < 0.05 
considered significant. 
3. RESULTS 
Having given their written informed consent, all patients 
were examined; no side effects were observed during the 
examinations. A total of 47 osteonecrotic lesions were 
detected in 30 patients (12 m; 18 f), fourteen afflicted by 
metastases of solid carcinomas (7 breast cancer, 3 pros- 
tate cancer and one respectively bladder, lung, kidney, 
mediastinal cancer), twelve by multiple myeloma, and 
one respectively by osteoporosis and palate osteosar- 
coma, chronic lymphocytic leukemia, non-Hodgkin 
lymphoma, osteoporosis. Onset of BRONJ was earlier in 
women (mean age 66.55 years old, min 43.25) than in 
men (mean age 68.12 years old, min 51.66) (Table 1). 
BRONJ occurred in 29 patients (96.60%) who had been 
treated with aminoBPs (zoledronate, pamidronate, alen- 
dronate). Zoledronate alone (4 mg IV every 4 weeks) 
was administered to 21 patients (70% of the series); 4 
patients (13.40%) switched from pamidronate to zole- 
dronate; other 2 patients (6.70%) received pamidronate 
(90 mg IV every 4 weeks): one (3.35%) pamidronate  
alone and one (3.35%) switched from zoledronate to pa- 
midronate; further 2 patients (6.70%) took alendronate 
(70 mg OS weekly). Only one patient (3.30%) with os- 
teoporosis took a bisphosphonate containing chlorine 
(100 mg IM weekly) (Table 2). The onset of BRONJ was 
earlier in patients receiving zoledronate, alone or fol- 
lowing pamidronate. The mean number of doses, ad- 
ministered IV, for patients affected by metastases of solid 
cancers, multiple myeloma, or osteoporosis + osteosar- 
coma, was 34.11 doses (min 8, max 61, SD + 12.15) in 
the case of zoledronate and 50.50 doses (minimum 37, 
maximum 64, SD ± 19.09) in the case of pamidronate. 
The single patient with chronic lymphocytic leukemia, 
and the one with non-Hodgkin’s lymphoma, respectively 
took 32 and approximately 260 oral doses of alendronate. 
The mean time to onset of ONJ was 146 weeks. However, 
patients also took high doses of corticosteroids to treat 
leukemia and lymphoma. Only one patient (3.30%) with 
osteoporosis took a bisphosphonate containing chlorine 
intramuscularly, approximately 500 doses (about 10 
years) (Table 2). Oral examination showed that 5 pa- 
tients were totally edentulous (4 women and 1 man), all 
wearing with removable dentures; in the 25 dentate pa- 
tients oral health status and oral hygiene were poor: the 
mean value of the plaque index (PI) was 2.00 and this 
one of gingival index (GI) was 1.85 (Table 3). Of the 47 
osteonecrotic lesions, 17 (36.15%) were in the maxilla (8 
right; 9 left) and 30 (63.85%) in the mandible (13 right; 
17 left). Sixteen patients had lesions in the mandible 
alone, 9 in the maxilla alone, and 5 had lesions in both 
jaws; this confirms reports in the literature indicating a 
higher percentage of BRONJ in the mandible. The stages 
of the lesions are reported in Table 4 and the trigger 
events are given in Table 5. Of our series, 23 patients 
(76.65%) reported symptoms, while 7 (23.35%) were 
completely asymptomatic at the time of observation. 
Twenty-one patients (70%) reported pain; 19 (63.30%) 
had signs of inflammation of the tissues surrounding the 
lesion; 13 (43.30%) showed swelling of the tissues sur- 
rounding the exposed bone; 13 (43.30%) reported diffi- 
culty in mastication; 3 (10%) had a cutaneous fistula; 2 
(6.70%) an oromaxillary fistula; 1 (3.30%) had a man- 
dibular fracture. The signs of BRONJ mentioned in the 
radiologists’ reports are “structural alteration of trabecu- 
lar bone, osteolytic lesion, cortical bone erosion, areas of 
bone destruction, osteosclerosis, radiolucent lesion cor- 
responding to empty socket, small or extensive ra- 
diopaque sequestra, presence of periosteal reaction, mu- 
coperiosteal thickening in the maxillary sinuses, oroan- 
tral communication” [26,35-38]. All patients (N = 30) at 
the time of the examination had a recent panoramic ra- 
diograph (OPT), but in only 8 (26.70%) cases signs of 
possible osteonecrosis have reported by radiologists; 
hirteen patients (43.30%) had a Computerized Axial  t 
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Table 1. Patients characteristics. BPs: Bisphosphonates; MM patients: patients affected by multiple myeloma; MTS: metastases of 
solid cancer. 
Male 12 (40.0%) 
Gender 
Female 18 (60.0%) 
Multiple Mieloma 12 (40%) 
Chronic lymphocytic leukemia 1 (3.33%) 
Non-Hodgkin’s lymphoma 1 (3.33%) 
Breast cancer 7 (23.3%) 
Prostate cancer 3 (10%) 
Bladder cancer 1 (3.33%) 
Lung cancer 1 (3.33%) 
Kidney cancer 1 (3.33%) 
Mediastinal cancer 1 (3.33%) 
Osteoporosis 1 (3.33%) 
Primary disease 
Palate osteosarcoma + Osteoporosis 1 (3.33%) 
Sample mean age at examination time 70.50 ± SD 9.62; min 45.50 max 85.83 
Males 71.69 ± SD 9.11; min 53.17 max 82.67 
Females 69.71 ± SD 10.13; min 45.50 max 85.83 
Sample mean age at diagnosis of primary disease 63.07 ± SD 10.89; min 39.00 max 80.91 
Males 64.93 ± SD 9.34; min 48.00 max 80.33 
Females 61.81 ± SD 11.91; min 39.00 max 80.91 
Sample mean age on starting BPs 65.48 ± SD 9.34; min 41.50 max 81.33 
Males 67.26 ± SD 8.61; min 51.25 max 75.00 
Females 61.30 ± 9.98; min 41.50 max 81.33 
Mean age on starting BPs in M.M. patients 67.75 ± SD 8.04; min 52.00 max 81.25 
in MTS of solid cancer patients 63.67 ± 10.67; min 41.50 max 81.33 
Sample mean age of onset of BRONJ 67.51 ± SD 8.97; min 43.25 max 82.41 
Males 68.12 ± SD 8.70; min 51.66 max 76.91 
Females 66.55 ± SDS 9.36; min 43.25 max 82.41 
Mean age of onset of BRONJ in MM patients 70.01 ± SD 7.61; min 54.58 max 81.42 
Age 
in MTS of solid cancer patients 65.32 ± SD 10.46; min 43.25 max 82.41 
 
Table 2. DRUGS. ZOL: zoledronate; PAM: pamidronate; ALE: alendronate; CLODR: clodronate. Patients MM: multiple myeloma; 
MTS: metastases of solid cancer; OST: osteoporosis; PO: palate osteosarcoma; CLL: Chronic lymphocytic leukemia; NHL: 
non-hodgkin lymphoma. ROUTE. IV: intravenous; OS: oral; IM: intramuscolar. 
DRUG PATIENTS ROUTE ONSET/DOSES 
ZOL 8 MM 12 MTS 1 OST + PO 21 70% 
PAM + ZOL 3 MM 1 MTS 4 13.30% 
25 83.30% 34.11 SD ± 12.15 min 8/max 61 every 28 days 
PAM 1 MM 1 3.35% 
ZOL + PAM 1 MTS 1 3.35% 
2 6.70% 
IV (27) 90%
50.50 SD ± 19.09 min 37/max 64 every 28 days 
ALE 1 CLL 1 NHL 2 6.70% 2 6.70% OS (2) 6.70% 146 SD ± 161.22 min 32/max 260 weekly 
CLODR 1 OST 1 3.30% 1 3.30% IM (1) 3.30% 500 weekly 
 
Tomography scan (CT) and in 12 cases the image 
showed clear signs of ONJ; ten patients (33.33%) had 
Nuclear Magnetic Resonance Imaging (MRI) and in 9 
cases the image showed clear signs of ONJ (Table 6). 
Statistical analysis of these data (Fisher exact test) 
showed that the panoramic radiograph does not provide 
useful information for diagnosis of BRONJ (p ≤ 0.04) 
and that stage 1 lesions have less probability of being 
identified than stage 2 or 3 lesions (OR = 6.1875, 95% 
CI 1.33 - 28.67) (Figure 1). Conversely, NMR and CT 
imaging offer a range of findings, depending on the stage 
and extension of lesions, confirming that these examina- 
tions are more reliable for diagnosing osteonecrotic le- 
sions. Used in combination with clinical findings, these 
imagines improve treatment planning [39-42]. Only 2 
patients with ONJ (6.70%) in our series had been sub-  
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Table 3. Data from oral examination.  
SAMPLE N SEX 
M = 11 
Dentate patients 25/30 
F = 14 
M = 1 
Edentulous patients 5/30 
F = 4 
M = 17.10 ± 6.99 
Mean teeth present 15.16 ± 7.70 
F = 13.64 ± 8.13 
M = 1.27 ± 2.83 
Mean teeth decayed 1.48 ± 2.46 
F = 1.64 ± 2.27 
M = 2.82 ± 3.43 
Mean teeth filled 2.24 ± 2.77 
F = 1.79 ± 2.15 
M = 0.45 ± 1.21 
Mean remaining roots 0.56 ± 1.16 
F = 0.64 ± 1.15 
Fixed = 16 Patients with  
prosthesis 17/30 Removable = 17 
M = 1 
Patients with implants 1/30 
F = 0 
M = 2.09 ± 0.85 
P.I. 2.00 ± 1.01 
F = 1.94 ± 1.13 
M = 2.02 ± 0.82 
G.I. 1.85 ± 0.93 
F = 1.74 ± 1.00 
Stage 1 




n = 14 (29.80%) 
6 Maxilla 
8 Mandible BRONJ n = 47 
Stage 3 




jected to a dental care protocol aimed at preventing os- 
teonecrosis before start of BP treatment. Seven patients 
in the series were treated with topical maintenance ther- 
apy only, 13 with topical and systemic pharmacological 
treatment to palliate symptoms associated with systemic 
infection of the tissues surrounding the area of osteone- 
crosis; 5 with topical, pharmacological and surgical revi- 
sion of the lesions under local anesthesia; 5 with topical, 
pharmacological, surgical revision under local anesthesia 
and surgical resection under general anesthesia. The 
outcome at six months was favorable in 6 cases, with 
complete repair of the tissues overlying the osteonecrotic 
lesion (3 treated with topical, pharmacological, and sur- 
gical revision of the lesion under local anesthesia; 3 also 
with surgery under general anesthesia); in 16 patients the 
lesion was unchanged (5 treated with topical therapy 
only; 11 with topical and systemic pharmacological trea- 
tment); in 4 patients the lesion deteriorated (2 treated 
with outpatient surgery; 2 with resection under general 
anesthesia) and 4 died before evaluation (2 treated with  
Table 4. Number and stage of lesions in the different quadrants 
(Q1 upper right, Q2 upper left, Q3 lower left, Q4 lower right) 
of the maxilla and mandible. 
Q1 = n 8 (17%) 
1 4 3 
Q2 = n 9 (19.15%) 
MAXILLA 
17 lesions (36.15%)
5 2 2 
13 (27.70%) 




9 4 4 
Stage 1 = 22 2 = 13 3 = 12
 
Table 5. Trigger of BRONJ in the patients of our sample af- 
flicted by: MM, multiple mieloma; MTS, metastases of solid 
cancer; CLL, Chronic lymphocytic leukemia; OST, osteopo- 
rosis; NHL, non Hodgkin’s lymphoma; OST/PO, osteoporosis 
and osteosarcoma of palate. 
CAUSES OF BRONJ n MM MTS CLL OST NHL OST/PO
EXTRACTIONS 31 66% 14 14 0 2 0 1 








6.40% 1 0 1 0 1 0 
PERIMPLANTITIS 1 2.10% 0 1 0 0 0 0 
 
Table 6. Total number of patients examinated; POS: positive 
report; NEG: negative report; OPT: Panoramic radiography; CT: 
Computerized axial tomography; MRI: nuclear magnetic reso- 
nance imaging. 
IMAGING TOTAL POS NEG 
OPT 30 (100%) 8 (26.70%) 22 (73.30%) 
CT 13 (43.30%) 12 (92.30%) 1 (7.70%) 
MRI 10 (33.35%) 9 (90%) 1 (10%) 
 
topical therapy alone; 2 treated with topical and systemic 
pharmacological treatment).  
4. DISCUSSION 
The link between the intake of BPs and osteonecrosis of 
the jaws emerged when reports appeared of these lesions 
in numerous patients receiving these drugs. Today, the 
body of evidence is sufficient to support a cause/effect 
relationship between BP exposure and osteonecrotic le- 
sions [14-24,26,28,30,31,37,41-48]. The incidence of 
BRONJ varies in different settings, and several other  
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Figure 1. Fisher exact test on sig-
nificance of panoramic radiograph 
(OPT) in diagnosing of BRONJ. 
 
risks factors have been indicated that might play a con- 
tributory role to the development of BRONJ: the local 
ones are consistent in literature, whereas the systemic 
ones (corticosteroids, diabetes, smoking, female gender) 
are controversial [14-17,20,23,25-28,30,32,37,43-48]. 
The type of amino-bisphosphonate (pamidronate diso- 
dium and zoledronic acid, which are commonly used to 
treat cancer patients), long-term therapy (high doses), 
and the intravenous administration route have been indi- 
cated as the principal risk factors in inducing BRONJ 
[14-26,43-49]. Few cases have been reported in patients 
treated with clodronate [29]. The first AAOMS Position 
Paper on Bisphosphonate-Related Osteonecrosis of the 
Jaws [14] subdivided BRONJ into three stages. A stage 0 
was added in a second revision [49], to include patients 
with no clinical evidence of necrotic bone, who present 
with non-specific symptoms or clinical and radiographic 
findings. The non-specific findings, which characterize 
stage 0, may occur in patients with temporary and de- 
finitive absence of bone exposure, but also in patients 
with a prior history of stage 1, 2, or 3 diseases who have 
healed and have no clinical evidence of exposed bone 
[49-51]. Treatment strategies are controversial and de-
pend on the stage of lesions and on Performance Status 
of the patients [14-16,26,28,39-43,45]. Patients who are 
only at risk of developing BRONJ because they have 
been exposed to a bisphosphonate should be informed, 
and achievement and/or maintenance of optimal perio- 
dontal and dental health is mandatory to prevent local 
risk factors inducing harm and exposure of the alveolar 
bone. Non-restorable teeth may be treated by removal of 
the crown and endodontic treatment of the remaining 
roots. Patients at stage 0 require symptomatic treatment, 
administration of medication for chronic pain, and con- 
trol of infection with antibiotics, when indicated. Patients 
at stage 1 benefit from the use of oral antimicrobial 
rinses, such as chlorhexidine 0.12%. Patients at stage 2 
benefit from the use of oral antimicrobial rinses in com- 
bination with antibiotic therapy. Patients at stage 3 bene- 
fit from debridement and in some cases bone resection, 
in combination with antibiotic therapy, which may offer 
long-term palliation with resolution of acute infection 
and pain [14-16,25,26,28,37,39-43,45,52-54]. Our study 
confirms that the panoramic radiograph underestimates 
the injury and the need to refer all patients with sus- 
pected bisphosphonate related osteonecrotic lesions on 
CT and MRI. 
5. CONCLUSION 
Bisphosphonate-related osteonecrosis of the jaws is a 
clinical and pathological entity that is not yet fully un- 
derstood; the true incidence of this adverse effect is al- 
most certainly underestimated. Many patients of our 
sample were sent from different Institution. For this rea- 
son it was not possible to subject all to the same imaging 
investigations and moreover, even to an untrained eye, 
evaluative discrepancies appear clearly between different 
radiologists. The most interesting findings of the current 
study are the lack of correlation between panoramic ra- 
diograph and osteonecrotic lesions, and the high grade of 
the plaque index and gingival index in patients of this 
series in spite of recommendations of maintaining a good 
oral hygiene to prevent oral diseases in patients at risk of 
BRONJ. In the expectation of results from research that 
may enable us to prevent osteonecrotic lesions, many 
works remain to be achieved to improve the education to 
oral health of physicians, dentists, dental hygienists and 
patients. 
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